![3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride (Intermediate Ⅰ of sitagliptin phosphate)](/upload/1124/V64275.png)
| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sitagliptin impurity
This compound does not possess a specific biological target, as it is a chemical intermediate rather than a therapeutic agent. Its role is purely synthetic, providing the structural framework for the final active pharmaceutical ingredient, sitagliptin, which targets the enzyme dipeptidyl peptidase-4 (DPP-4). The intermediate itself is not designed to interact with biological systems, and any biological effects are attributed to the downstream drug molecules synthesized from it. |
|---|---|
| ln Vitro |
An impurity of Sitagliptin and intermediate for the synthesis of Sitagliptin
Biological in vitro activity is not applicable for this compound, as it is not evaluated for pharmacological effects. Its "activity" is chemical in nature, involving its ability to undergo specific transformations, such as coupling reactions, to form the sitagliptin structure. Researchers use it as a reagent to construct the pyrazine ring system, which is essential for the DPP-4 inhibitory activity of the final drug. No in vitro potency or efficacy data exist for this intermediate. |
| ln Vivo |
No in vivo activity is reported for this compound, as it is not administered to living organisms for therapeutic or investigative purposes. Its use is confined to the chemistry laboratory, where it is transformed into active drugs. Any in vivo effects, such as glucose-lowering actions, are associated with sitagliptin, not with this precursor. The compound itself does not exhibit pharmacological properties in animal models.
|
| Enzyme Assay |
In a typical synthetic procedure, this intermediate is reacted with other chemical entities under controlled conditions to form sitagliptin phosphate. For example, it may undergo nucleophilic substitution or condensation reactions in the presence of appropriate bases and solvents. The reaction progress is monitored by thin-layer chromatography (TLC) or high-performance liquid chromatography (HPLC), and the product is purified by crystallization or column chromatography to achieve the required purity for pharmaceutical use.
|
| Cell Assay |
This compound is not used in cell-based assays, as it is not a biologically active molecule. Its application is restricted to organic synthesis, and it is not added to cell culture media for any experimental purpose. Researchers focus on its chemical behavior, such as stability and reactivity, rather than its effects on cellular functions. Consequently, no standard cellular protocols exist for this intermediate.
|
| Animal Protocol |
Animal studies are not conducted with this intermediate, as it is not a drug candidate. It serves exclusively as a building block for the synthesis of drugs that are subsequently tested in vivo. For instance, sitagliptin, derived from this intermediate, is evaluated in diabetic animal models for its efficacy in lowering blood glucose. The intermediate itself is never administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are irrelevant for this chemical intermediate, as it is not intended for systemic exposure. Its physical and chemical characteristics, such as molecular weight (228.60 g/mol) and purity (typically ≥97%), are well documented. It is a solid powder that is stable under recommended storage conditions. Its solubility in organic solvents facilitates its use in synthetic reactions, but no absorption, distribution, metabolism, or excretion data are available.
|
| Toxicity/Toxicokinetics |
Toxicological information for this compound is not extensively detailed in public literature, as it is a research reagent. Standard laboratory safety precautions should be followed, including the use of personal protective equipment and working in a fume hood. It may cause irritation upon contact with skin or eyes, and inhalation should be avoided. A safety data sheet (SDS) should be consulted for comprehensive hazard information before handling.
|
| References |
[1]. A kind of sitagliptin impurity I and preparation method thereof. CN-113979896-A
|
| Additional Infomation |
This compound is a commercially available research chemical primarily used as a pharmaceutical intermediate. Its most significant application is in the synthesis of sitagliptin phosphate, a leading medication for type 2 diabetes. Additionally, derivatives of this triazolopyrazine scaffold have been explored for antimicrobial and other biological activities, highlighting its versatility. It is not approved for clinical use and is strictly intended for laboratory research and drug development.
|
| Molecular Formula |
C6H8CLF3N4
|
|---|---|
| Molecular Weight |
228.60
|
| Exact Mass |
192.062
|
| CAS # |
762240-92-6
|
| PubChem CID |
11961371
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
266.2±50.0 °C at 760 mmHg
|
| Melting Point |
236-246ºC
|
| Flash Point |
114.8±30.1 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
-0.21
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
195
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].FC(C1=NN=C2C([H])([H])N([H])C([H])([H])C([H])([H])N21)(F)F
|
| InChi Key |
AQCSCRYRCRORET-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7F3N4.ClH/c7-6(8,9)5-12-11-4-3-10-1-2-13(4)5;/h10H,1-3H2;1H
|
| Chemical Name |
3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine;hydrochloride
|
| Synonyms |
762240-92-6; 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride; 3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride; Sitagliptin Impurity 18; Y0OF5KV5KA; 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine hydrochloride; UNII-Y0OF5KV5KA; MFCD09817638;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (437.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3745 mL | 21.8723 mL | 43.7445 mL | |
| 5 mM | 0.8749 mL | 4.3745 mL | 8.7489 mL | |
| 10 mM | 0.4374 mL | 2.1872 mL | 4.3745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
